Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating
Autore:
Binder, EB; Kinkead, B; Owens, MJ; Kilts, CD; Nemeroff, CB;
Indirizzi:
Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Lab Neuropsychopharmacol, Atlanta, GA 30322 USA Emory Univ Atlanta GA USA 30322 uropsychopharmacol, Atlanta, GA 30322 USA Max Planck Inst Psychiat, D-80804 Munich, Germany Max Planck Inst Psychiat Munich Germany D-80804 D-80804 Munich, Germany
Titolo Testata:
JOURNAL OF NEUROSCIENCE
fascicolo: 2, volume: 21, anno: 2001,
pagine: 601 - 608
SICI:
0270-6474(20010115)21:2<601:ENNIII>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
CENTRAL-NERVOUS-SYSTEM; LATENT INHIBITION; SCHIZOPHRENIC-PATIENTS; PREPULSE INHIBITION; STRIATAL DOPAMINE; GABA RELEASE; RAT; DEFICITS; RECEPTOR; BRAIN;
Keywords:
prepulse inhibition; latent inhibition; haloperidol; quetiapine; SR 142948A; isolation rearing;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
57
Recensione:
Indirizzi per estratti:
Indirizzo: Nemeroff, CB Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Lab Neuropsychopharmacol, Suite 4000 WMRB,1639 Pierce Dr, Atlanta, GA 30322 USA Emory Univ Suite 4000 WMRB,1639 Pierce Dr Atlanta GA USA 30322
Citazione:
E.B. Binder et al., "Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating", J NEUROSC, 21(2), 2001, pp. 601-608

Abstract

To date, none of the available antipsychotic drugs are curative, all have significant side-effect potential, and a receptor-binding profile predictive of superior therapeutic ability has not been determined. It has become increasingly clear that schizophrenia does not result from the dysfunction ofa single neurotransmitter system, but rather from an imbalance between several interacting systems. Targeting neuropeptide neuromodulator systems that concertedly regulate all affected neurotransmitter systems could be a promising novel therapeutic approach for schizophrenia. A considerable database is concordant with the hypothesis that antipsychotic drugs act, at least in part, by increasing the synthesis and release of the neuropeptide neurotensin (NT). In this report, we demonstrate that NT neurotransmission is critically involved in the behavioral effects of antipsychotic drugs in two models of antipsychotic drug activity: disrupted prepulse inhibition of the acoustic startle response (PPI) and the latent inhibition (LI) paradigm. Blockade of NT neurotransmission using the NT receptor antagonist 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)- N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole-3- carbonyl]-amino]-adamantane-2-carboxylic acid, hydrochloride (SR 142948A) prevented the normal acquisition of LI and haloperidol-induced enhancement of LI. In addition, SR 142948A blocked the PPI-restoring effects of haloperidol and the atypical antipsychotic drug quetiapine in isolation-reared animals deficient in PPI. We also provide evidence of deficient NT neurotransmission as well as a left-shifted antipsychotic drug dose-response curve in isolation-reared rats. These novel findings, together with previous observations, suggest that neurotensin receptor agonistsmay represent a novel class of antipsychotic drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/11/19 alle ore 03:21:03